How it started
History
Fosun Pharmaceutical is a listed company which started A share initial public offering in 1998 and H share in 2012. The English name of the company was initially known as Shanghai Fortune Industrial Joint-Stock Co., Ltd. (SFIC; Chinese: 上海复星实业股份有限公司), but the transliteration of 复星 was later changed from Fortune to Fosun (as Fosun Industrial), as well as changing the name from Industrial (Chinese: 实业) to Pharmaceutical (Chinese: 医药). The company also shorten the transliteration of the legal suffix 股份有限公司 from Joint-Stock Co., Ltd. to just Co., Ltd..
Shanghai Fortune Industrial Joint-Stock Co., Ltd. was incorporated in 1998, but its predecessor, Shanghai Fortune Industrial Company (Chinese: 上海复星实业公司) was incorporated in January 1994. The majority shareholders in December 1994 were Fosun High Technology (Chinese: 复星高科技) and its parent company Guangxin Technology (Chinese: 广信科技); Guangxin Technology was owned by Guo Guangchang, Liang Xinjun, Wang Qunbin and Fan Wei.
In 2003 Fosun Pharmaceutical acquired 49% stake of Sinopharm Group (Chinese: 国药控股). In 2008, a year before the initial public offering of Sinopharm Group, Fosun Pharmaceutical owned the direct parent company of Sinopharm Group, Sinopharm Industrial Investment (Chinese: 国药产业投资) instead; the majority owner of the joint venture was state-owned China National Pharmaceutical Group (Sinopharm).
An intermediate parent company of Fosun Pharma, Fosun International (parent company of Fosun High Technology), became a listed company in 2007.
In 2014 Fosun Pharma was part of a consortium to acquire US-listed Chindex International, which owned private hospitals in mainland China.
From Wikipedia’s article on Fosun Pharmaceutical, shared under CC BY-SA 4.0.2